Making a measurable differenceEliA CTD Screen, the most clinically relevant and reliable CTD Screen, helps simplify patient diagnosis
Streamlining connective tissue disease (CTD) diagnosticsThe EliA™ CTD Screen workflow can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1*,2**
EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8
90.4-93.4% negative1*, 2** Common panel
Refer to specialist
care
Complex case panels
EliA CTD Screen
EliA dsDNA test
EliA Mi-2 test
EliA Fibrillarin test
EliA PCNA test
EliA RNA Pol III test
EliA Rib-P test
EliA PM-Scl test
EliA Ro test
EliA La test
EliA U1RNP test
EliA Scl-70s test
EliA SmDp test
EliA Jo-1 test
EliA CENP test
Primary Differentiators
Secondary Differentiators
*Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen.**Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.
if from Primary Care
The superior specificity of EliA CTD Screen, based on 2,000 patients being tested, and a disease prevalence of 1%, leads to 158 fewer false positives per year.8
100
50
0EliA CTD Screen ANA IIF
92%84%
SensitivitySpecificity
90%76%
Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.
Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.
*Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen. **Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.
Simplifying laboratory life Optimised workflow – supporting your lean approach
Your partner – offering the complete support package to make the transition to EliA CTD Screen smooth
One operator, one footprint, one maintenance, one service programme, one solution for allergy and autoimmunity
No manual preparation necessary and with the flexibility to load and unload carriers
The same wash buffer, stop solution, development solution – improving cost and time efficiencies
One calibration curve per method stored for one month (IgG, IgM, IgA, IgE, calprotectin, anti-TSH-R) – maximising workflow efficiencies
Ability to run requests as and when they arriveHigh on-board carrier/test capacity
Ready to use carriers/reagents
System reagents are suitable for both EliA and ImmunoCAPTM tests
Efficient, flexible, calibration system
One system, one sample, multiple tests
Educational meetings for
your laboratory
Scientific support with results
interpretation
Letter for HCP to understand why/what has
changed
Support with educational
meetings for your clinical customers
Making a measurable differenceWhy choose Thermo Fisher Scientific as your partner in connective tissue disease diagnostics?
Streamlined diagnoses
EliA CTD Screen; a single test that includes 17 autoantibodies; can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1,2
Accurate results
EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8
Efficient workflow
EliA CTD Screen is run on a fully automated, workflow optimised, Phadia™ Instrument, helping increase turnaround time in your laboratory
REFERENCES1. Willems P, et al. Clin Chem Lab Med 2018;56;909-18. 2. Robier C, et al. Clin Chem Lab Med 2016;54(8):1365-70.3. Korsholm T, et al. Scand J Rheumatol 2014;43:89. 4. Pereira LM, et al. EliA Journal 2010 (Special Edition 1):6-7.5. Alpini C, et al. EliA Journal 2010 (Special Edition 1):3.18. 6. Otten HG, et al. Clin Exp Rheumatol 2017.7. Jeong S, et al. PLoS ONE 2017;12(3). 8. van der Pol P, et al. Clinica Chimica Acta 2018;476:154-159.
Find out more at allergyai.com/uk/lab© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 2019-26.AI.EU1.EN.v1.19